Cardiovascular Risk Estimation and Eligibility for Statins in Primary Prevention Comparing Different Strategies

被引:12
|
作者
Nanchen, David [1 ,2 ]
Chiolero, Arnaud [2 ]
Cornuz, Jacques [1 ]
Marques-Vidal, Pedro-Manuel [2 ]
Firmann, Mathieu [3 ]
Mooser, Vincent [4 ]
Paccaud, Fred [2 ]
Waeber, Gerard [3 ]
Vollenweider, Peter [3 ]
Rodondi, Nicolas [1 ]
机构
[1] Univ Lausanne, Univ Hosp Ctr, Dept Ambulatory Care & Community Med, Lausanne, Switzerland
[2] Univ Lausanne, Univ Hosp Ctr, Inst Social & Prevent Med, Lausanne, Switzerland
[3] Univ Lausanne, Univ Hosp Ctr, Dept Med, Lausanne, Switzerland
[4] GlaxoSmithKline, Div Genet, King Of Prussia, PA USA
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2009年 / 103卷 / 08期
关键词
CORONARY-HEART-DISEASE; EUROPEAN GUIDELINES; FRAMINGHAM; POPULATION; THERAPY; SCORE; EPIDEMIOLOGY; PARTICIPANTS; METAANALYSIS; MORTALITY;
D O I
10.1016/j.amjcard.2008.12.042
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recommendations for statin use for primary prevention of coronary heart disease (CHID) are based on estimation of the 10-year CHD risk. It is unclear which risk algorithm and guidelines should be used in European populations. Using data from a population-based study in Switzerland, we first assessed 10-year CHD risk and eligibility for statins in 5,683 women and men 35 to 75 years of age without cardiovascular disease by comparing recommendations by the European Society of Cardiology without and with extrapolation of risk to age 60 years, the International Atherosclerosis Society, and the US Adult Treatment Panel III. The proportions of participants classified as high-risk for CHD were 12.5% (15.4% with extrapolation), 3.0%, and 5.8%, respectively. Proportions of participants eligible for statins were 9.2% (11.6% with extrapolation), 13.7%, and 16.7%, respectively. Assuming full compliance to each guideline, expected relative decreases in CHD deaths in Switzerland over a 10-year period would be 16.4% (17.5% with extrapolation), 18.7%, and 19.3%, respectively; the corresponding numbers needed to treat to prevent 1 CHD death would be 285 (340 with extrapolation), 380, and 440, respectively. In conclusion, the proportion of subjects classified as high risk for CHD varied over a fivefold range across recommendations. Following the International Atherosclerosis Society and the Adult Treatment Panel III recommendations might prevent more CHD deaths at the cost of higher numbers needed to treat compared with European Society of Cardiology guidelines. (C) 2009 Elsevier Inc. All rights reserved. (Am J Cardiol 2009;103:1089-1095)
引用
收藏
页码:1089 / 1095
页数:7
相关论文
共 50 条
  • [1] Statins for Cardiovascular Prevention According to Different Strategies A Cost Analysis
    Ito, Marcia K.
    Nanchen, David
    Rodondi, Nicolas
    Paccaud, Fred
    Waeber, Gerard
    Vollenweider, Peter
    Marques-Vidal, Pedro
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2011, 11 (01) : 33 - 44
  • [2] Statins for primary prevention of cardiovascular disease
    Byrne, Paula
    Cullinan, John
    Smith, Susan M.
    BMJ-BRITISH MEDICAL JOURNAL, 2019, 367
  • [3] Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks
    Minder, C. Michael
    Blumenthal, Roger S.
    Blaha, Michael J.
    CURRENT OPINION IN CARDIOLOGY, 2013, 28 (05) : 554 - 560
  • [4] Statins for primary prevention of cardiovascular disease in Germany: benefits and costs
    Dressel, Alexander
    Fath, Felix
    Kraemer, Bernhard K.
    Klose, Gerald
    Maerz, Winfried
    CLINICAL RESEARCH IN CARDIOLOGY, 2025,
  • [5] High Risk versus Proportional Benefit: Modelling Equitable Strategies in Cardiovascular Prevention
    Marchant, Ivanny
    Boissel, Jean-Pierre
    Nony, Patrice
    Gueyffier, Francois
    PLOS ONE, 2015, 10 (11):
  • [6] Statins for the primary prevention of cardiovascular disease
    Ebrahim, Shah
    Taylor, Fiona C.
    Brindle, Peter
    BMJ-BRITISH MEDICAL JOURNAL, 2014, 348
  • [7] Statins for primary cardiovascular prevention in the elderly
    Pedro-Botet, Juan
    Climent, Elisenda
    Chillaron, Juan J.
    Toro, Rocio
    Benaiges, David
    Flores-Le Roux, Juana A.
    JOURNAL OF GERIATRIC CARDIOLOGY, 2015, 12 (04) : 431 - 438
  • [8] Statins for primary prevention of cardiovascular disease
    Deckers, Jaap W.
    Blumenthal, Roger S.
    BMJ-BRITISH MEDICAL JOURNAL, 2011, 342
  • [9] Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population-Based Cohort Study
    Garcia-Gil, Maria
    Comas-Cufi, Marc
    Blanch, Jordi
    Marti, Ruth
    Ponjoan, Anna
    Alves-Cabratosa, Lia
    Petersen, Irene
    Marrugat, Jaume
    Elosua, Roberto
    Grau, Maria
    Ramos, Rafel
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (04) : 719 - 732
  • [10] Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews
    Byrne, Paula
    Cullinan, John
    Smith, Amelia
    Smith, Susan M.
    BMJ OPEN, 2019, 9 (04):